Results 181 to 190 of about 27,400 (237)

Contemporary Treatment Patterns in Surgically Treated Temporal Bone Cancer

open access: yesThe Laryngoscope, EarlyView.
In a national cohort of 811 surgically treated temporal bone cancer patients, adjuvant radiation therapy was the most frequently utilized postoperative treatment (20.3%), while chemotherapy and immunotherapy were used far less frequently. Multimodal treatment, particularly combined parotidectomy and neck dissection, was strongly associated with higher ...
Raquel Rowell   +4 more
wiley   +1 more source

The FOXQ1/SSBP2 Regulatory Axis Drives Malignant Progression of Melanoma

open access: yesMolecular Carcinogenesis, EarlyView.
ABSTRACT Melanoma is a highly aggressive skin cancer with poor prognosis, often linked to excessive UV exposure. Despite advancements in immunotherapy and targeted treatments, melanoma's invasiveness and metastatic potential remain significant challenges.
Xiaoyu Zhang   +4 more
wiley   +1 more source

Multiomics Insights Into AL Amyloidosis

open access: yesMedicine Bulletin, EarlyView.
ABSTRACT Light chain amyloidosis is a systemic or localized protein conformational disorder triggered by misfolded immunoglobulin light chains, leading to amyloid fibril deposition. The disease is characterized by multiorgan involvement and delayed diagnosis, contributing to poor prognosis and high mortality rates.
Zixuan Zhang   +6 more
wiley   +1 more source

Artificial Intelligence for Identifying Tumor‐Reactive CD8+ T Cells: Biological Principles, Computational Advances, and Future Directions

open access: yesMed Research, EarlyView.
This review details a three‐stage paradigm shift for tumor‐reactive CD8+ T‐cell identification: decoding transcriptomic states, deciphering clonal functional efficacy, and molecular‐level therapeutic TCR design. Addressing translational hurdles and generative AI “scientific blind spots”—such as missing catch bonds—we present a visionary roadmap.
Chao Yang   +4 more
wiley   +1 more source

Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials. [PDF]

open access: yesNat Med
Porter ML   +22 more
europepmc   +1 more source

Organoid Coculture Models for Cancer Research and Immunotherapy

open access: yesMed Research, EarlyView.
This review summarizes organoid coculture platforms, including submerged Matrigel culture, air–liquid interface, microfluidic/organoid‐on‐a‐chip, and 3D bioprinting, for reconstructing the tumor microenvironment to study tumor–stroma/immune crosstalk, evaluate immunotherapies, and enable drug screening.
Zhuo Yang   +9 more
wiley   +1 more source

Vaccinology in the twenty-first century revisited. [PDF]

open access: yesNPJ Vaccines
Barrett ADT   +3 more
europepmc   +1 more source

Differential FGFR1 copy number status displays unique tumour immune microenvironment in triple‐negative breast cancer

open access: yesThe Journal of Pathology, EarlyView.
Abstract Fibroblast growth factor receptor 1 (FGFR1) amplification, a significant cancer alteration with both prognostic and therapeutic relevance, lacks a standardized definition. The relationship between FGFR1 copy number (CN) variations and tumour microenvironment (TME) characteristics also remains poorly understood.
Yike Gao   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy